EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Metabolomic Signatures of Relapse and Survival in AML Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation

Igor Novitzky-Basso iD, Changjiang Xu, Caden Chiarello, Julie A Reisz, Angelo D'Alessandro iD, Gary D Bader iD, Jonas Mattsson, Courtney Jones

Hematology Reports · 07.04.2026 · 18 (2) · 27

DOI: 10.3390/hematolrep18020027 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hematology Reports, online erschienen am 07.04.2026. Verfasst von Igor Novitzky-Basso und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Allogeneic stem cell transplantation (HSCT) is curative in acute myeloid leukemia (AML) but is limited by relapse and non-relapse mortality (NRM). Metabolomic prognostic value is unclear. We assessed whether plasma metabolite profiles at diagnosis, pre-transplant, and post-transplant are associated with overall survival (OS) and cause-specific mortality.

Methods

We retrospectively analyzed plasma metabolites from 63 AML patients undergoing HSCT (263 samples).

Results

Higher levels of valine (hazard ratio [HR] 24.454), citrulline (HR 20.478), 5-oxoproline (HR 11.766), and glutamine (HR 8.701) associated with higher NRM, while inosine diphosphate (HR 0.091) and pyridoxamine-5′-phosphate (HR 0.313) associated with lower NRM. For relapse-related mortality (RRM), higher levels of phenylalanine (HR 26.585), leucine/isoleucine (HR 10.755), indolepyruvate (HR 7.676), and creatinine (HR 13.874) were associated with higher RRM, while trans-4-hydroxy-L-proline (HR 0.101) was associated with lower RRM. Higher post-transplant ornithine (HR 0.063), 3-sulfocatechol (HR 0.590), and indole-3-acetate (HR 0.359) were associated with improved OS. Mixed-effects modelling identified lower dehydroascorbate and citrate in relapsed patients, with dehydroascorbate remaining significant after false discovery rate adjustment.

Conclusions

Metabolomic profiling nominated candidate metabolites for validation in larger prospective studies and elucidated mechanistic pathways, potentially informing novel interventions or risk-adapted monitoring strategies in HSCT.

Schlagwörter

Stichwörter der Autor:innen

acute myeloid leukemiaallogeneic stem cell transplantmetabolomics

Autor:innen und Institutionen

  • Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada.
  • Department of Medicine, University of Toronto, Toronto, ON M5S 1A1, Canada.
  • The Donnelly Centre, University of Toronto, Toronto, ON M5S 1A1, Canada.
  • Department of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
  • Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.

ORCID-Profile: Igor Novitzky-Basso, Angelo D'Alessandro, Gary D Bader

Zitieren

APA

Novitzky-Basso, I., Xu, C., Chiarello, C., Reisz, J. A., D'Alessandro, A., Bader, G. D., Mattsson, J., & Jones, C. (2026). Metabolomic Signatures of Relapse and Survival in AML Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. Hematology Reports, 18(2), 27. https://doi.org/10.3390/hematolrep18020027

Vancouver

Novitzky-Basso I, Xu C, Chiarello C, Reisz JA, D'Alessandro A, Bader GD, et al. Metabolomic Signatures of Relapse and Survival in AML Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. Hematology Reports. 2026;18(2):27. doi:10.3390/hematolrep18020027

BibTeX
@article{NovitzkyBasso2026,
  author = {Novitzky-Basso, Igor and Xu, Changjiang and Chiarello, Caden and Reisz, Julie A and D'Alessandro, Angelo and Bader, Gary D and Mattsson, Jonas and Jones, Courtney},
  title = {Metabolomic Signatures of Relapse and Survival in AML Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation},
  journal = {Hematology Reports},
  year = {2026},
  volume = {18},
  number = {2},
  pages = {27},
  doi = {10.3390/hematolrep18020027}
}
Kostenlos starten →